RevolKa Ltd., a venture-backed biotech company with a protein engineering technology platform, and La Jolla Institute for Immunology (LJI) have initiated a research collaboration to create antigens for next-generation vaccines to address unmet medical needs in infectious diseases.   RevolKa has a robust directed protein evolution technology integrated with artificial intelligence (AI), called aiProtein, which is trained with sequence-function relationship data to statistically predict sequence...